Conversely, the implication from our results is that EGFR-TKI may suppress tumor sensitivity to NK cells via down-regulation of the expression of NKG2D ligands, as was shown by the attenuation of NK cell-mediated cytotoxicity by Gefitinib. This evidence concerns the gene EGFR and neoplasm.